In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelin...
Sipavibart reduced symptomatic COVID-19 by 34.9% compared to standard treatment, but efficacy was only observed against non–Phe456Leu-containing variants, according to new phase 3 trial data.
Researchers found that awake prone positioning was associated with improved survival without intubation and reduced mortality in patients with COVID-19 and acute hypoxemic respiratory failure.
In a new study on the long-term health risks post–COVID-19 hospitalization, researchers reported an "increased risk of death or hospitalization for various organ disorders up to 30 months after discharge."